News | February 05, 2025
Pfizer reports 2024 revenues 7% higher at $63.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Subscribe To Our Newsletter & Stay Updated
